Advertisement
The phase 1 trial aimed to investigate the enhanced in vivo anti-tumor activity of a fully humanized CAR T targeting mesothelin compared to a murine-derived counterpart, focusing on improving persistence and efficacy. Researchers noticed enhanced M5 CAR T cell persistence in mesothelin-expressing cancers, suggesting avenues for improving clinical outcomes in CAR T cell […]...
Advertisement
Advertisement
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Advertisement
Advertisement
Background Cancer neoantigens arise from protein-altering somatic mutations in tumor and rank among the most promising next-generation immuno-oncology agents when used in combination with immune checkpoint inhibitors. We previously developed a computational framework, REAL-neo, for identification, …
Background Only a subset of patients with gastric cancer experience long-term benefits from immune checkpoint inhibitors (ICIs). Currently, there is a deficiency in precise predictive biomarkers for ICI efficacy. The aim of this study was to …
Background Chimeric antigen receptor (CAR) T cell therapies specific for the CD19 and B-cell maturation antigen have become an approved standard of care worldwide for relapsed and refractory B-cell malignancies. If CAR-T cell therapy for non-hematological …
Background Cancer-intrinsic type I interferon (IFN-I) production triggered by radiotherapy (RT) is mainly dependent on cytosolic double-stranded DNA (dsDNA)-mediated cGAS/STING signaling and increases cancer immunogenicity and enhances the antitumor immune response to increase therapeutic efficacy. However, …
